<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174174</url>
  </required_header>
  <id_info>
    <org_study_id>920203l</org_study_id>
    <nct_id>NCT00174174</nct_id>
  </id_info>
  <brief_title>Provigil (Modafinil) Study by Taiwan Biotech Co.</brief_title>
  <official_title>A Placebo Control, Double Blind, Cross Over Study of Modafinil in Patients With Narcolepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the therapeutic effect of excessive daytime sleepiness&#xD;
      associated with narcolepsy. Both of the subjective and objective sleepiness of the patients&#xD;
      were assessed in the experiment by repeat measures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in the sleep latency.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's assessment of general level of daytime sleepiness on ESS.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's cognitive function assessed by psychomotor function test (Trail making test, and Digit Symbol Substitution Test).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's sleep quality evaluated by PSQI.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety would be evaluated by tabulating and summarizing all adverse events reported.</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Narcolepsy</condition>
  <condition>Cataplexy</condition>
  <condition>Sleep Disorders</condition>
  <condition>Hypersomnolence</condition>
  <condition>Excessive Sleepiness</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Polysomnographic findings of shortened sleep latency less than 5 minutes average of&#xD;
             Multiple Sleep Latency Test, and two or more SOREM should be fulfilled.&#xD;
&#xD;
          -  Age of 12 y/o to 55 y/o.&#xD;
&#xD;
          -  The liver and kidney functions are within normal limits.&#xD;
&#xD;
          -  Meeting the strict criteria of narcolepsy described above.&#xD;
&#xD;
          -  Wash out any medications which might enhance wakefulness or affect nocturnal sleep two&#xD;
             weeks prior to the experiments.&#xD;
&#xD;
          -  Willingness to comply with the protocol and signed the written Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whose hypersomnia was caused by severely sleep deprived, phase delayed, or&#xD;
             suspected long sleeper.&#xD;
&#xD;
          -  Patients with concomitant neurological disorder and psychiatric disorders.&#xD;
&#xD;
          -  Patients with sleep-related breathing disorders whose apnea/hypopnea index (AHI) was 5&#xD;
             pauses per hour above.&#xD;
&#xD;
          -  Patients with Restless Leg Syndrome &amp; Periodic Limbs Movements whose index was more&#xD;
             than 5 per hour.&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yue-Joe Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, National Taiwan University</affiliation>
  </overall_official>
  <verification_date>October 2004</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 14, 2005</last_update_submitted>
  <last_update_submitted_qc>September 14, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

